Why is it so hard to get my ADHD medication in the US?
Obviously, I made sure to bring as much Vyvanse as possible with me. “As much as possible” turned out to be two months’ worth, and the first month of our return was occupied exclusively with finding a place to live. Once that was sorted, though, my Vyvanse supply had started to wane, and with a…#vyvanse #vicodin #hoo (Source: Reuters: Health)
Source: Reuters: Health - October 18, 2023 Category: Consumer Health News Source Type: news

One Year Later, Where ’s All the Adderall?
The U.S. is facing a mystery of missing Adderall—one for which nobody has an answer. Oct. 12 marked one year since the U.S. Food and Drug Administration’s formal announcement that pharmaceutical companies were unable to produce enough Adderall, one of the common amphetamine-based medications for attention-deficit/hyperactivity disorder (ADHD). As a result, many of the 41 million ADHD patients nationwide who rely on the drug daily to stay focused and reduce impulsive behavior have faced refill delays and empty inventories at their pharmacies. [time-brightcove not-tgx=”true”] Eight drug manuf...
Source: TIME: Health - October 17, 2023 Category: Consumer Health News Authors: Haley Weiss Tags: Uncategorized healthscienceclimate Source Type: news

Why is it now so hard to get my ADHD medication? | Tom Hawking
I moved to New York this year and am embroiled in a Kafkaesque ordeal trying to get my meds filledBack in 2019, I was diagnosed with ADHD at age 40, a process I describedfor the Guardian. The diagnosis came as a surprise to me, but not to anyone I knew: sure, I ’d never been especially hyperactive (or even, y’know, active), but the chronic lateness, difficulty concentrating, lack of emotional self-regulation and decades-long struggle to locate my keys … these were all classic symptoms.I was prescribed a medication called Vyvanse, which I ’ve been taking daily since. It’s proven immensely helpful, allowing me to s...
Source: Guardian Unlimited Science - October 16, 2023 Category: Science Authors: Tom Hawking Tags: Health Science Life and style Healthcare industry Health policy Mental health Pharmaceuticals industry Source Type: news

Delayed-Release ADHD Therapy Slightly Mitigates Slowed Growth in Kids
(MedPage Today) -- NASHVILLE -- Youth with attention-deficit/hyperactivity disorder (ADHD) saw mildly different growth trajectories with certain popular medications, researchers reported. Compared with youth prescribed lisdexamfetamine dimesylate... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - September 10, 2023 Category: Neurology Source Type: news

Generic Drugmakers Start Shipping Copies of ADHD Drug Generic Drugmakers Start Shipping Copies of ADHD Drug
Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical ' s drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2023 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)
DUBLIN, Aug. 31, 2023 -- (Healthcare Sales & Marketing Network) -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that its Specialty Generics segment, operating as SpecGx LLC, received approval on August 25, ... Biopharmaceuticals, Generics, FDA Mallinckrodt, SpecGx, lisdexamfetamine, ADHD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 31, 2023 Category: Pharmaceuticals Source Type: news

FDA OKs ADHD Generics; Flotation Therapy; Civilians Respond to Distress Calls
(MedPage Today) -- The FDA approved the first generic forms of lisdexamfetamine dimesylate (Vyvanse) capsules and chewables to treat attention deficit-hyperactivity disorder (ADHD) in patients 6 years and older, as well as moderate to severe binge... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - August 30, 2023 Category: Psychiatry Source Type: news

Vaccine Skepticism Spreads to Pets; Generics for ADHD Approved; Malaria in Maryland
(MedPage Today) -- Note that some links may require registration or subscription. Some dog owners questioned pet vaccines like rabies, survey data showed. (Vaccine) The FDA approved multiple generics of lisdexamfetamine dimesylate to treat attention... (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - August 29, 2023 Category: Pediatrics Source Type: news

Generics of Vyvanse, Takeda's ADHD drug, get FDA green light
Takeda Pharmaceutical Company Limited just lost exclusivity on its ADHD drug. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 28, 2023 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news

FDA Approves First Generics for Vyvanse
August 28, 2023 -- FDA has approved several first generics of Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets for attention-deficit/hyperactivity disorder (ADHD) in patients six years and older and moderate to severe binge-eating... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 28, 2023 Category: General Medicine Source Type: news

Manufacturing delays hit Takeda's Vyvanse amid ADHD drug shortage
Takeda Pharmaceutical Company Limited is facing a manufacturing delay for its ADHD drug, Vyvanse, just as shortages for other ADHD drugs roil the country. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 15, 2023 Category: Biotechnology Authors: Rowan Walrath Source Type: news

Takeda braces for impact as Vyvanse edges toward the patent cliff
As several of Takeda’s top-earning drugs veer toward the patent cliff, the Japanese drugmaker is buckling up for a bumpy ride. | Bracing for losses of exclusivity on a pair of drugs this year, Takeda has forecasted 3,840 billion yen (about $28.5 billion) in revenues for fiscal year 2023, an…#takeda (Source: Reuters: Health)
Source: Reuters: Health - May 13, 2023 Category: Consumer Health News Source Type: news

ADHD Medication Might Help In Treating Amphetamine Addiction
A recent JAMA Psychiatry study found that an ADHD medicine called lisdexamfetamine reduced the risk of hospitalization due to amphetamine or methamphetamine addiciton by 18% and 14% for deaths caused by substance abuse disorders. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 25, 2022 Category: Pharmaceuticals Authors: Anuradha Varanasi, Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news

Drug May Curb ‘ Sluggish ’ Thinking in Some Adults With ADHD
Lisdexamfetamine found to reduce symptoms of sluggish cognitive tempo in small group of adults with ADHD (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - July 2, 2021 Category: Psychiatry Tags: Pharmacy, Psychiatry, Journal, Source Type: news

Drug May Curb'Sluggish' Thinking in Some Adults With ADHD
THURSDAY, July 1, 2021 -- Lisdexamfetamine reduces symptoms of sluggish cognitive tempo (SCT) in adults with attention-deficit/hyperactivity disorder (ADHD), according to a study published online June 29 in the Journal of Clinical Psychiatry. In a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 1, 2021 Category: Pharmaceuticals Source Type: news